Pharmaceutical Regulation, Bioethics and Healthcare Justice: A Critical Legal Analysis of Biologic Therapies and Insurance Accessibility in IBD Treatment in India

Inflammatory Bowel Disease (IBD) is a chronic disease that needs to be treated on an ongoing basis by a physician, and in some instances, by a high-level specialist in disease management. The development of biologic treatments has significantly enhanced the treatment of moderate to severe IBD by offering specific treatment options for patients who don't get enough benefit from conventional drugs. But the prices of biologic drugs and their restrictions in regulatory approval and availability in health insurance policies pose challenges to their access in India. In this paper, the connection between pharmaceutical regulation, bioethical concepts and healthcare justice to ensure access to biologic treatments is critically analysed. It follows a doctrinal and analytical legal research method using Indian pharmaceuticals laws, guidelines and regulations, intellectual property laws, health insurance laws and constitutional principles and precedents. The study explores the effectiveness of the regulatory framework and the current insurance schemes and the ethical issues presented by differential access to more sophisticated treatments. It believes that if the medicine is approved and marketed, it does not necessarily mean that there is some meaningful access to healthcare. A concerted effort with lower drug costs, appropriate biosimilar regulation and better insurance coverage and public healthcare support is required. The paper concludes that access to medically required biologic treatment is an integral part of a healthcare system's duty to "do justice" and should not come at the price of people's ability to afford it.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-15
DOI
https://doi.org/10.5281/zenodo.24248810
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmaceutical Regulation, Bioethics and Healthcare Justice: A Critical Legal Analysis of Biologic Therapies and Insurance Accessibility in IBD Treatment in India

Adv. Mrunal Dhamale
Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Economics and Policy
article

Pharmaceutical Regulation, Bioethics and Healthcare Justice: A Critical Legal Analysis of Biologic Therapies and Insurance Accessibility in IBD Treatment in India

Adv. Mrunal Dhamale
article en

Abstract

Inflammatory Bowel Disease (IBD) is a chronic disease that needs to be treated on an ongoing basis by a physician, and in some instances, by a high-level specialist in disease management. The development of biologic treatments has significantly enhanced the treatment of moderate to severe IBD by offering specific treatment options for patients who don't get enough benefit from conventional drugs. But the prices of biologic drugs and their restrictions in regulatory approval and availability in health insurance policies pose challenges to their access in India. In this paper, the connection between pharmaceutical regulation, bioethical concepts and healthcare justice to ensure access to biologic treatments is critically analysed. It follows a doctrinal and analytical legal research method using Indian pharmaceuticals laws, guidelines and regulations, intellectual property laws, health insurance laws and constitutional principles and precedents. The study explores the effectiveness of the regulatory framework and the current insurance schemes and the ethical issues presented by differential access to more sophisticated treatments. It believes that if the medicine is approved and marketed, it does not necessarily mean that there is some meaningful access to healthcare. A concerted effort with lower drug costs, appropriate biosimilar regulation and better insurance coverage and public healthcare support is required. The paper concludes that access to medically required biologic treatment is an integral part of a healthcare system's duty to "do justice" and should not come at the price of people's ability to afford it.

Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon